After approval of its gene product NFκB decoy oligo for treatment of disc spondylosis (spinal degeneration) by FDA, Anges MG will launch clinical tests in the USA within the first half of 2017, and the outcome will be known in 2019.

Anges MG news release, April 24, 2017